81 results
8-K
EX-99.1
bvbxxjgzc68 xme
28 Apr 21
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
hp09h8zhakwlci9ia5
3 May 18
Teva Reports First Quarter 2018 Financial Results
12:00am
DEF 14A
mtwc34znvci kf
25 Apr 18
Definitive proxy
12:00am
6-K
EX-99.1
podcs 0y2bd
18 Aug 17
Teva Announces Exclusive Launch of Generic Axiron® In the United States
12:00am
6-K
EX-99.1
k9f06 7hajdb4ob8k
24 Jul 17
Live Filing
12:00am
6-K
EX-99.1
4vdym
30 Sep 15
IMPORTANT NEW DATA FROM TEVA’S TEV-48125 PHASE 2b MIGRAINE PROGRAM PUBLISHED INLANCET NEUROLOGYIN BACK-TO-BACK ARTICLES
12:00am
6-K
EX-99.1
w3lr33fn
23 Mar 15
Live Filing
12:00am
6-K
EX-99.1
g9f2ei trisgs
24 Feb 15
TEVA ANNOUNCES POSITIVE RESULTS FOR TEV-48125 IN PHASE IIb CHRONIC MIGRAINE STUDY MEETING PRIMARY AND SECONDARY ENDPOINTS
12:00am
6-K
EX-99.1
kmnjln
3 Sep 14
Teva Launches Syncaretm Home Administration Support Program for Patients on Synribo® (Omacetaxine Mepesuccinate) for Injection
12:00am